Clinical Report: Jiangzhi Ruanmai Formula Mitigates Atherosclerosis in ApoE−/− Mice

Overview

Expand on the mechanisms linking JZRM effects to cholesterol metabolism and gut microbiota modulation.

Background

Atherosclerosis is a major contributor to cardiovascular diseases, characterized by arterial plaque formation and increased risk of acute events such as myocardial infarction. Current treatments primarily focus on statins, but residual risks remain, necessitating exploration of alternative therapies. The gut microbiota's role in cholesterol metabolism presents a novel avenue for therapeutic intervention in atherosclerosis.

Data Highlights

Key Findings

• JZRM reduced lipid and glucose levels in ApoE−/− mice.
• Decreased aortic plaque area was observed following JZRM treatment.
• JZRM increased the abundance and diversity of gut microbiota.
• Enhanced expression of proteins involved in cholesterol transport (ABCA1, ABCG1) was noted.
• JZRM modulated bile acid metabolism through the FXR/CYP7A1 pathway.

Clinical Implications

The findings suggest that JZRM may serve as a complementary therapy for managing atherosclerosis by improving cholesterol metabolism and gut microbiota health. Clinicians should consider the potential of herbal formulations like JZRM in conjunction with standard treatments to enhance patient outcomes.

Conclusion

Highlight the types of clinical studies needed to further validate the findings.

Related Resources & Content

1. Basic Research in Cardiology, 2020 -- Macrophage Proliferation Inhibition is Key to Plaque Regression Following Cholesterol Reduction
2. Journal of Gastroenterology, 2024 -- Resistant starch inhibits glycolysis via HK2 and mitigates colon tumor development induced by high-fructose corn syrup
3. Basic Research in Cardiology, 2020 -- Reduced Levels of Nucleotide-binding Oligomerization Domain Proteins 1 and 2 Impair Atherosclerosis Development
4. Frontiers in Cardiovascular Medicine, 2026 -- GLP-1 receptor agonists alleviate inflammatory responses and endothelial dysfunction in atherosclerosis by activating the Sema3A/NRP1 pathway
5. 2026 Guideline on the Management of Dyslipidemia - Professional Heart Daily | American Heart Association
6. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine
7. Gut microbiome and metabolome profiling in Framingham Heart Study reveals cholesterol-metabolizing bacteria
8. 2026 Guideline on the Management of Dyslipidemia - Professional Heart Daily | American Heart Association
9. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | New England Journal of Medicine
10. Gut microbiome and metabolome profiling in Framingham Heart Study reveals cholesterol-metabolizing bacteria - PMC